Fig. 4
The effects of IL6 on ccRCC cells migration and the IL6/STAT3 signaling pathway. CcRCC cells (769-P and ACHN) were treated with 1640 or 1640 + IL6 (200 μg/ml), NF-CM or NF-CM + anti-IL6 (50 μg/ml) for 48 h. a Cells migration ability was measured by transwell assays. Migration cells at 48-h time point were presented. ***P < 0.001 vs. 1640. Anti-IL6 antibody (50 μg/ml) inhibited the effect. **P < 0.01, ***P < 0.001 vs. NF-CM. b P-STAT3, STAT3, MMP2, and MMP9 were analyzed using western blotting. Values represent the mean ± SD from three independent experiments. *P < 0.05, **P < 0.01 1640 vs. 1640 + IL6, NF-CM vs. NF-CM + anti-IL6. Note that recombinant human IL6 could promote ccRCC cells migration and activate STAT3 and MMP2, while anti-IL6 antibody could abolish the effect
